Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DIA Workshop on Clinical Trials Discusses AE Reporting
March 14, 2005
- FY2005 Plan for Promoting Blood Donation Approved
March 7, 2005
- REGULATORY NEWS IN BRIEF
March 7, 2005
- Prospects for Integration of Sankyo, Daiichi Analyzed: Datamonitor
March 7, 2005
- NEW PRODUCTS
March 7, 2005
- Suzuken Creating Customer-focused Marketing System
March 7, 2005
- Annual Business Results
March 7, 2005
- GE Marketing Association Petitions for Revision of NHI Price System
March 7, 2005
- 1st 3 Qtrs Business Results
March 7, 2005
- JPMA Prepares "Implementation Manual" for Revised Charter
March 7, 2005
- BUSINESS FORECAST
March 7, 2005
- Domestic Pharma Firms Losing Employees: JPMA DATA BOOK 2005
March 7, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 7, 2005
- Sales of JCROA Member Firms Increase 22.6% in 2004
March 7, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 7, 2005
- Results of Survey on Ethical Drug Development Announced: Fuji-Keizai
March 7, 2005
- OTC Drug Industry Should Take Advantage of Booming Health Food Market: Mr Futagawa of MED
March 7, 2005
- BUSINESS NEWS IN BRIEF
March 7, 2005
- Experts Generally Agree on Risk Assessment Method for OTC Drugs
March 7, 2005
- PRESS SEMINAR
March 7, 2005
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…